# A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

> **NCT06504862** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Zongertinib
- **DRUG:** Dabigatran-etexilate
- **DRUG:** Rosuvastatin
- **DRUG:** Metformin hydrochloride
- **DRUG:** Furosemide

## Key facts

- **NCT ID:** NCT06504862
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-20
- **Primary completion:** 2024-10-03
- **Final completion:** 2024-12-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504862, "A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06504862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*